Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

Franziska Wachter, MD

  • Physician
  • Instructor in Pediatrics, Harvard Medical School

Office Phone

  • 617-632-3270

Appointment Phone

  • 617-632-3270

Fax

  • 617-632-1990

General

Treatment Centers

Location

Background

Board Certifications

  • Pediatric Oncology, 2022
  • Pediatrics, 2020

Fellowship

  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Pediatric Hematology/Oncology, 2022

Residency

  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics, 2019

Medical School

  • LMU Munich Medical School, 2013

Biography

Dr. Wachter is a physician-scientist committed to combining compassionate, leading-edge care of malignancies with groundbreaking research in experimental therapeutics.  She obtained her MD from Ludwig Maximillans University, Munich, Germany and graduated summa cum laude from Irmela Jeremia's laboratory, where she studied mechanisms of chemoresistance and the influence of p53 reactivation responses to the extrinsic apoptotic pathway agonist TRAIL.  

She then continued her training in Loren Walensky's laboratory, which focuses on interrogating BCL-2 family protein biology through the lens of structural and chemical biology.  Dr. Wachter's particular areas of study comprised investigating inhibitory mechanisms of the pro-apoptotic effector protein BAX as well as identifying and characterizing BAX activators identified in an NMR-based fragment screen.  She also validated the on-target mechanism of a p53 reactivating stapled peptide drug.  Currently, she continues her postdoc scientific training in Eric Fischer's laboratory co-mentored by Scott Armstrong and use modern structural biology methods and biochemistry with the goal to structurally define aberrant transcription in myeloid children with high-risk myeloid malignancies.

Dr. Wachter attends on the pediatric stem cell transplant service, and her clinical interest is to improve outcomes for pediatric AML and MDS after stem cell transplant.  Her clinical research efforts focus on the role of novel therapeutics in the treatment of high-risk acute myeloid leukemia, with a special focus on disease control prior to hematopoietic stem cell transplant (HCT) and maintenance treatment after HCT to reduce the risk of relapse.